Most recent guideline publication
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017)
Updates since publication:
No updates on dosing recommendations since publication.
Tables provided in the main manuscript of the guideline:
|Table 1. Assignment of HLA-B and HLA-A genotypes|
|Table 2. Recommendations for carbamazepine therapy based on HLA-B and HLA-A genotypes|
|Table 3. Recommendations for oxcarbazepine therapy based on HLA-B genotype|
Supplement to: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017)
Tables included in the supplement or referenced in the guidelinea:
|Supplemental Table S1. Evidence linking HLA-B*15:02 genotype with carbamazepine- and oxcarbazepine-induced cutaneous adverse reactions|
|Supplemental Table S2: Evidence linking HLA-A*31:01 genotype with carbamazepine-and oxcarbazepine-induced cutaneous adverse reactions|
|HLA-A frequency tables
HLA-B frequency tables
|Gene resource mapping
HLA-A gene reources mapping
HLA-B gene reources mapping
|Drug resource mapping
|Clinical decision supportb:|
aSome of the tables included in the guideline may have been updated online, particularly to reflect newly described or newly characterized alleles. These include the gene-specific information tables (https://www.pharmgkb.org/page/pgxGeneRef) that support CPIC guidelines by providing information regarding star (*) allele definitions, allele function, allele frequency by major ethnic groups, translations of diplotype to phenotype, and gene resource mappings.
bThese resources support the adoption of CPIC guidelines into the electronic health record with clinical decision support and provide information that clinical implementers find helpful.
Original guideline publication (September 2013):
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Carbamazepine Dosing (September 2013)
Supplement to: Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Carbamazepine Dosing (September 2013)